admin

Expert Rev Respir Med. 2025 Sep 4. doi: 10.1080/17476348.2025.2557634. Online ahead of print. ABSTRACT INTRODUCTION: To evaluate… Read More

J Clin Invest. 2025 Sep 4:e192669. doi: 10.1172/JCI192669. Online ahead of print. ABSTRACT BACKGROUND: In human lupus… Read More

Z Rheumatol. 2025 Sep 4. doi: 10.1007/s00393-025-01709-w. Online ahead of print. ABSTRACT BACKGROUND: Comics are increasingly being… Read More

Curr Osteoporos Rep. 2025 Sep 4;23(1):36. doi: 10.1007/s11914-025-00929-y. ABSTRACT PURPOSE OF REVIEW: In this review, we will… Read More

Zhonghua Nei Ke Za Zhi. 2025 Sep 1;64(9):891-899. doi: 10.3760/cma.j.cn112138-20240927-00610. ABSTRACT 系统性红斑狼疮（SLE）的发病机制复杂，目前治疗选择相对有限。Ⅰ型干扰素通路作为同时调控固有与适应性免疫的核心致病机制，已成为药物研发关键靶点。靶向Ⅰ型干扰素受体的anifrolumab 是近十年首个获批治疗中重度SLE的创新生物制剂。围绕Ⅰ型干扰素的产生和受体激活通路的多种靶向治疗药物正处于不同研发阶段。各靶向药物在临床应用中表现出不同的疗效和特点，差异可能源于作用机制特异性及患者异质性。本综述系统阐述Ⅰ型干扰素通路致病机制与靶向治疗策略的前沿进展，旨在为临床精准用药提供理论依据。. PMID:40904301 | DOI:10.3760/cma.j.cn112138-20240927-00610 Read More

Clin Rheumatol. 2025 Sep 4. doi: 10.1007/s10067-025-07665-9. Online ahead of print. ABSTRACT OBJECTIVES: We aimed to explore… Read More

Rheumatol Int. 2025 Sep 4;45(9):217. doi: 10.1007/s00296-025-05963-8. ABSTRACT BACKGROUND: VEXAS syndrome (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic)… Read More

Ther Adv Musculoskelet Dis. 2025 Sep 1;17:1759720X251371112. doi: 10.1177/1759720X251371112. eCollection 2025. ABSTRACT BACKGROUND: Impaired lung function has… Read More

Clin Rheumatol. 2025 Sep 4. doi: 10.1007/s10067-025-07671-x. Online ahead of print. ABSTRACT OBJECTIVES: Pulmonary hemorrhage (PH) represents… Read More